Ophthalmic drug delivery has gained significant attention because of its potential to deliver drugs directly to the eye without systemic exposure. Explore the challenges to effective delivery to the eye, the intricacies of ophthalmic drug delivery, and the advantages of nanoparticles as an enabling technology for ocular drug-delivery systems.
Christian Jones, CCO of Nanoform, discusses what it truly means to be patient-centric in the modern pharmaceutical industry. Discover the challenges pharma companies are facing as they switch focus as well as the actions and technologies companies are implementing to help achieve a brighter future for patients.
Glioblastoma multiforme (GBM) is the most common type of malignant primary brain tumor. It is difficult to treat and has a high risk of recurrence after surgery, placing efficacious treatments in high demand. Find new possibilities for increased dosing capabilities and diffusion across the brain parenchyma offered by nanoformed APIs.
Nanoform’s proprietary bionanoparticle technology can deliver large-molecule drug particles as small as 50 nm while retaining biological activity. This can not only enable more patient-friendly approaches to drug delivery, but also potentially higher loads of active ingredients.
